Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michael Thomenius"'
Autor:
Sarah K. Knutson, Scott Ribich, Allison Drew, Heike Keilhack, Igor Feldman, J. Joshua Smith, Danielle Johnston-Blackwell, Michael Thomenius, Christopher Plescia, Elayne Chan-Penebre, Trupti Lingaraj, Robert A. Copeland, Vinny Motwani, Alejandra Raimondi, Natalie Warholic, Dorothy Brach
Publikováno v:
Molecular Cancer Therapeutics. 16:2586-2597
The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase II clinical trials for the treatment of non-Hodgkin lymphoma (NHL). We have previously shown that EZH2 inhibitors display an antiproliferative effect in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cba4e6445ef53b25230ed1edf2577da9
https://doi.org/10.1158/1535-7163.mct-16-0840
https://doi.org/10.1158/1535-7163.mct-16-0840
Autor:
Jennifer Totman, Kevin Wayne Kuntz, Megan Alene Cloonan Foley, Lorna Helen Mitchell, Nathalie Rioux, Thomas V. Riera, James Edward John Mills, Suzanne L. Jacques, Robert A. Copeland, Tim J. Wigle, Alejandra Raimondi, Kip A. West, P. Ann Boriack-Sjodin, Sherri Smith, Margaret Porter Scott, Michael John Munchhof, Christine Klaus, Michael Thomenius, Nigel J. Waters, J. Joshua Smith, Richard Chesworth
Publikováno v:
ACS Medicinal Chemistry Letters. 7:134-138
SMYD3 has been implicated in a range of cancers; however, until now no potent selective small molecule inhibitors have been available for target validation studies. A novel oxindole series of SMYD3 inhibitors was identified through screening of the E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2276a83671eb4bf0b31912fb398a2e24
https://doi.org/10.1021/acsmedchemlett.5b00272
https://doi.org/10.1021/acsmedchemlett.5b00272
Autor:
Cuyue Tang, Michael John Munchhof, Kat Cosmopoulos, Kip A. West, Mikel P. Moyer, Sherri Smith, Lorna Helen Mitchell, Margaret Porter Scott, Haris Jahic, Alexandra R. Grassian, Megan Alene Cloonan Foley, Thomas V. Riera, Darren Martin Harvey, Scott Ribich, P. Ann Boriack-Sjodin, Kevin Wayne Kuntz, Nigel J. Waters, Dorothy Brach, Christine Klaus, J. Joshua Smith, Robert A. Copeland, Trupti Lingaraj, Elizabeth A. Admirand, Jennifer Totman, Michael Thomenius, Christina R. Majer, Tim J. Wigle, Richard Chesworth, Alejandra Raimondi, Jodi Gureasko, Nathalie Rioux, James Edward John Mills, Suzanne L. Jacques, William P. Janzen
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 6, p e0197372 (2018)
PLoS ONE, Vol 13, Iss 6, p e0197372 (2018)
A key challenge in the development of precision medicine is defining the phenotypic consequences of pharmacological modulation of specific target macromolecules. To address this issue, a variety of genetic, molecular and chemical tools can be used. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db6179ff168da8f29fc3b07b8965b83d
https://pubmed.ncbi.nlm.nih.gov/29856759
https://pubmed.ncbi.nlm.nih.gov/29856759
Autor:
Lorna Helen Mitchell, James Edward John Mills, J. Joshua Smith, Nathalie Rioux, Christine Klaus, Thomas V. Riera, Nigel J. Waters, Paula Ann Boriack-Sjodin, Suzanne L. Jacques, Sherri Smith, Michael Thomenius, Kevin Wayne Kuntz, Michael John Munchhof, Megan Alene Cloonan Foley, Richard Chesworth, Jennifer Totman, Robert A. Copeland, Tim J. Wigle, Alejandra Raimondi, Margaret Porter Scott
Publikováno v:
Molecular Cancer Therapeutics. 14:C85-C85
SMYD3 (Set and Mynd Domain containing 3) is a lysine methyltransferase overexpressed in several cancer types including breast, prostrate, pancreatic, and lung, and this overexpression is associated with poor clinical prognosis. Genetic knockdown of S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba2ceb125f31c5783539d9ea0acf81e1
https://doi.org/10.1158/1535-7163.targ-15-c85
https://doi.org/10.1158/1535-7163.targ-15-c85
Autor:
Trupti Lingaraj, Alison Drew, Danielle Johnston, Scott Ribich, Alejandra Raimondi, Dorothy Brach, Sarah K. Knutson, Heike Keilhack, Christopher Plescia, Natalie Warholic, Robert A. Copeland, J. Joshua Smith, Elayne Penebre, Michael Thomenius
Publikováno v:
Molecular Cancer Therapeutics. 14:B85-B85
The EZH2 inhibitor tazemetostat (EPZ-6438) is emerging as a promising therapeutic agent for the treatment of non-Hodgkin's Lymphoma (NHL). A significant body of work has now demonstrated in vitro and in vivo effects of EZH2 inhibition in preclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e2c75d285a6e354196cddb94e68049f
https://doi.org/10.1158/1535-7163.targ-15-b85
https://doi.org/10.1158/1535-7163.targ-15-b85